APM
NXTC icon

Avidity Partners Management’s NextCure NXTC Stock Holding History

Avidity Partners Management’s Portfolio NXTC Stock Details NXTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-7,750
Closed -$5.24M – 61
2019
Q4 		$5.24M Buy
+7,750
New +$3.89M 3.3% 13

Other funds holding NXTC

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
CPX
Canaan Partners X Menlo Park, California $74.7M AUM 151.56% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Avidity Partners Management's NXTC Position: Q1 2020 in Review

Avidity Partners Management sold out of NextCure (NXTC) in Q1 2020, closing a stake of 7,750 shares — an estimated $5.24M sold.

Avidity Partners Management first reported a position in NXTC in Q4 2019 and held it in 1 quarter. The position peaked at $5.24M in Q4 2019. 82 funds tracked by Wall St. Rank hold NXTC as of Q1 2020.

  • Avidity Partners Management reported no remaining NextCure position as of Q1 2020 after selling out during the quarter.
  • Avidity Partners Management sold 7,750 NextCure shares in Q1 2020, an estimated $5.24M.
  • Avidity Partners Management first reported a position in NextCure in Q4 2019 and held it in 1 quarter.
  • Avidity Partners Management's NextCure position peaked at $5.24M in Q4 2019.
  • 82 funds tracked by Wall St. Rank held NextCure as of Q1 2020.

Based on Avidity Partners Management's 13F filing for Q1 2020, filed 15 May 2020.